John R. Stanley

faculty photo
Emeritus Professor of Dermatology
Department: Dermatology

Contact information
University of Pennsylvania School of Medicine
Department of Dermatology
421 Curie Boulevard
Philadelphia, PA 19104
B.A. (Physics)
Cornell University, 1970.
Harvard Medical School, 1974.
Permanent link

Description of Itmat Expertise

My laboratory is interested in two main areas:
1) The pathophysiology of autoimmune blistering skin diseases (e.g. pemphigus and pemphigoid). We are now characterizing the autoantibody response by cloning monoclonal antibodies from pemphigus patients, allowing us to genetically characterize pathogenic and non-pathogenic antibodies. These antibodies are being used to study the pathophysiology of disease and to screen for new targeted therapy for these diseases.
2) Development of a targeted drug delivery system. In cloning monoclonal antibodies from pemphigus patients, we found that most bound epidermis but caused no pathology. These cloned antibodies are simple single chain variable fragments, 25 kD molecules in which the variable heavy and light chain are joined by a small linker to fold into an active antigen combining site. We think that such molecules could be useful for drug delivery to the epidermis.

Selected Publications

Chen J, Zheng Q, Hammers CM, Ellebrecht CT, Mukherjee EM, Tang HY, Lin C, Yuan H, Pan M, Langenhan J, Komorowski L, Siegel DL, Payne AS, Stanley JR: Proteomic analysis of pemphigus autoantibodies indicates a larger, more diverse, and more dynamic repertoire than determined by B-cell genetics. Cell Reports 18: 237-247, 2017.

Yoshida K, Ishii K, Shimizu A, Yokouchi M, Amagai M, Shiraishi K, Shirakata Y, Stanley JR, Ishiko A: Non-pathogenic pemphigus foliaceus (PF) IgG acts synergistically with a directly pathogenic PF IgG to increase blistering by p38MAPK-dependent desmoglein 1 clustering. J Dermatol Sci 85: 197-207, 2017.

Hammers CM, Stanley JR: Mechanisms of Disease: Pemphigus and bullous pemphigoid. Annual Review of Pathology: Mechanisms of Disease 11: 175-197, 2016.

Hammers CM, Chen J, Lin C, Kacir S, Siegel DL, Payne AS, Stanley JR: Persistence of anti-desmoglein 3 IgG B-cell clones in pemphigus patients over years. J. Invest. Dermatol. 135: 742-749, 2015.

Toumi A, Saleh MA, Yamagami J, Abida O, Kallel M, Masmoudi A, Makni S, Turki H, Hachiya T, Kuroda K, Stanley JR, Masmoudi H, Amagai M: Autoimmune reactivity against precursor form of desmoglein 1 in healthy Tunisians in the area of endemic pemphigus foliaceus. J Dermatol Sci doi: 10.1016/j.jdermsci.2013.02.002. Epub 2012 Feb 19, 70(1): 19-25 April 2013.

Kouno K, Lin C, Schechter N, Siegel D, Yang X, Seykora JT, Stanley JR: Targeted delivery of tumor necrosis factor-related apoptosis-inducing ligand to keratinocytes with a pemphigus monoclonal antibody. J Invest Dermatol February 2013 Notes: Advance online publication 4 April 2013; doi: 10.1038/jid.2013.85.

Hammers CM, Stanley JR: Antibody phage display: Technique and applications J. Invest. Dermatol. 134:e17(doi:10.1038/jid 2013.521), 2013.

Hammers CM, Stanley JR: Desmoglein-1, differentiation, and disease. J. Clin. Invest. Doi:10.1172/JCI69071, 2013.

Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, Tsai DE, Payne AS: Adjuvant rituximab therapy of pemphigus: A single center experience with 31 patients. Arch Dermatol 148: 1031-1036, 2012.

Yamagami J, Payne AS, Kacir S, Ishii K, Siegel DL, Stanley JR: Homologous regions of heavy chain complementarity determining region 3 (H-CDR3) of pemphigus antibodies cause pathogenicity. J Clin Invest 120: 4111-4117, 2010.

back to top
Last updated: 07/12/2017
The Trustees of the University of Pennsylvania